Pfizer Inc's diabetes drug resulted in weight loss similar to that of Novo Nordisk's Ozempic in a mid-stage study testing it in patients with type 2 diabetes, according to data published in a medical journal.
The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. REUTERS/Carlo Allegri/File Photodiabetes drug resulted in weight loss similar to that of Novo Nordisk's Ozempic in a mid-stage study testing it in patients with type 2 diabetes, according to data published in a medical journal.
Peer reviewed data from the mid-stage study, which evaluated 411 adults with type 2 diabetes, who received either the drug or a placebo, was published in JAMA network on Monday.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Pfizer Quickly Climbs to High; Pfizer Oral Weight Loss Drug May Be as Effective as, Quicker Than Novo Nordisk's Ozempic - CNBC By Investing.comPfizer Quickly Climbs to High; Pfizer Oral Weight Loss Drug May Be as Effective as, Quicker Than Novo Nordisk's Ozempic - CNBC
Lire la suite »
Golnesa 'GG' Gharachedaghi Opens Up About Taking Ozempic (Exclusive)Golnesa 'GG' Gharachedaghi is opening up about losing weight on the anti-obesity and antidiabetic medication.
Lire la suite »
Thai Inc shakeup could follow shock election winThe winning party remains upbeat it can form a government. Institutional reform is top of Move Forward’s agenda, but its wish list includes breaking up monopolies and cutting state concessions. The $500 bln economy needs a competitive upgrade. It will come at tycoons’ expense.
Lire la suite »
Workers Want Ozempic for Weight Loss. Few Employers Want to Pay for It.Many Americans seeking drugs like Ozempic to shed pounds are hitting a barrier: their employer health plans.
Lire la suite »
Novo Nordisk says trial of oral weight-loss drug shows significant resultNovo Nordisk said on Monday a late-stage trial of an oral version of its drug semaglutide for weight loss has shown statistically significant and superior weight loss when compared to a placebo.
Lire la suite »
Japan's Mizuho expands in U.S. banking with $550 mln Greenhill dealMizuho Financial Group Inc will buy U.S. M&A advisory firm Greenhill & Co Inc for $550 million including debt, the companies said on Monday, as Japan's No. 3 lender eyes a bigger share of the world's largest investment-banking fee pool.
Lire la suite »